Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$3.93 USD
-0.21 (-5.07%)
Updated May 17, 2024 03:04 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 341 - 360 ( 426 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q FY16, Fate Looks Compelling Ahead of Data-Rich Year, Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fate Adds to iPSC Technology, Expanded Platform Promising Immuno-oncology Play, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH Presentations Showcase Versatility of Technology Platform
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional ASH Updates for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ProTmune Trial Protocol Amended; Impressive Preclinical ASH Lineup
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q16: Rejigging the PROTECT Study May Have Long-term Payoff for ProTmune
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ProTmune Study Protocol Amended to Support Potential for Accelerated Approval, Trimming Price Target to $7 (from $8)
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The A to Z of HSCT: InvestorÂ’s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage of Fate Therapeutics, Inc. with a Buy rating and a target price of $8
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q16: Fate May Have Two New Programs in the Clinic in 2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 EPS; ProTmune Study Underway; Pipeline Programs Advance Towards Clinic in Early 2017
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Tech Stacked Deck; Assuming Coverage With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D